CGS-CIMB Research predicts Kotra's ROE to remain steady at a...
CGS-CIMB Research predicts Kotra's ROE to remain steady at around 18% in FY25-FY26 due to improved economies of scale. They also forecast a 3% annual rise in local pharmaceutical product revenue and a 6-8% increase in export revenue in FY24-FY26.
Kotra's Long-term ROE Expected to Hold Steady
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4315Followers
0Following
9477Visitors
Follow